Spruce Biosciences Inc SPRB.OQ SPRB.O is expected to show a fall in quarterly revenue when it reports results on November 11 (estimated) for the period ending September 30 2024
The South San Francisco California-based company is expected to report a 51.4% decrease in revenue to $1.494 million from $3.07 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Spruce Biosciences Inc is for a loss of 24 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Spruce Biosciences Inc is $2.50, above its last closing price of $0.55.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jan. 1 0001 | -0.32 | -0.32 | -0.22 | Beat | 31.4 |
Mar. 31 0001 | -0.29 | -0.29 | -0.28 | Beat | 3.2 |
Dec. 31 2023 | -0.39 | -0.39 | -0.24 | Beat | 37.8 |
Sep. 30 2023 | -0.36 | -0.35 | -0.30 | Beat | 15.1 |
Jun. 30 2023 | -0.39 | -0.39 | -0.32 | Beat | 18.4 |
Mar. 31 2023 | -0.33 | -0.36 | -0.40 | Missed | -10.4 |
Dec. 31 2022 | -0.56 | -0.53 | -0.47 | Beat | 11.3 |
Sep. 30 2022 | -0.54 | -0.53 | -0.48 | Beat | 10.3 |
This summary was machine generated November 8 at 15:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments